RRRaihan Rabbani

Raihan Rabbani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raihan Rabbani has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh

    by Jahidul Hasan, Raihan Rabbani, Ahmad Mursel Anam, Shihan Mahmud Redwanul Huq

    Hyperinflammation-induced respiratory failure is a leading cause of mortality in COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are the drug-of-choice to sup...


  • Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?

    by Jahidul Hasan, Raihan Rabbani, Ahmad Mursel Anam, Shihan Mahmud Redwanul Huq


  • Open Access

    Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh

    by Jahidul Hasan, Raihan Rabbani, Ahmad Mursel Anam, Shihan Mahmud Redwanul Huq, Mohammad Mufizul Islam Polash, Shahzadi Sayeeda Tun Nessa, Sitesh C. Bachar

    Purpose: Hyperinflammation in severe COVID-19 infection increases the risk of respiratory failure and one of the cogent reasons of mortality associated with COVID-19. Baricitinib, a janus kinases inhibitor, can potentially suppress inflammatory cascades in severe COVID-19 pneumonia.Methods: The objective of this study was to compare the clinical outcomes of high dose of baricitinib with its usual dose in patients with severe COVID-19 pneumonia. This prospective cohort study was conducted on 238 adult patients with severe COVID-19 pneumonia. Eight milligram and 4 mg of baricitinib was given orally to 122 patients in the high dose (HD) group and 116 patients the usual dose (UD) group, respectively daily for 14 days, and clinical outcomes were compared among the groups.Results: Blood oxygen saturation level was stabilized (≥94% on room air) earlier in the HD group compared to the UD group [5 (IQR: 4–5)/8 (IQR: 6–9),P < 0.05]. Patients in the HD group required intensive care unit (ICU) and intubation supports more in the UD group than that in patients of the HD group [17.2%/9%,P < 0.05; 11.2%/4.1%,P > 0.05;N = 116/122, respectively]. The 30-day mortality and 60-day rehospitalization rate were higher in the UD group than the HD group [6%/3.3%,P < 0.01; 11.9%/7.6%,P > 0.05;N = 116/122, respectively].Conclusion: The daily high dose of baricitinib in severe COVID-19 results in early stabilization of the respiratory functions, declined requirements of critical care supports, reduced rehospitalization with mortality rate compared to its daily usual dose.


  • Open Access

    Impact of Comorbidities on Clinical Outcome of Patients with COVID-19: Evidence from a Single-center in Bangladesh

    by Jahidul Hasan, Ahmad Mursel Anam, Shihan Mahmud Redwanul Huq, Raihan Rabbani

    Background: COVID-19 patients with preexisting comorbidities are at increased risk of exacerbated symptoms. Objectives: The current study aimed to firstly assess the impact of predisposed comorbidities on the severity of COVID-19, and secondly investigating the associated clinical outcome of patients with COVID-19 infection in Bangladesh. Methods: In this single-center retrospective study, the medical data of 157 hospitalized COVID-19 patients, including their preexisting comorbidities, from April 30, 2020, to June 15, 2020, are analyzed. Patients’ clinical outcomes in moderate-to-critical COVID-19 infections need for Intensive Care Unit (ICU) and mechanical ventilation support, and mortality were evaluated, with emphasis on predisposed chronic diseases. Results: Approximately 40.1 and 7.6% of patients (n = 157) presented severe and critical COVID-19 symptoms, respectively (P = 0.001). The most common comorbidity was diabeties (24.8%), followed by hypertension (23.2). Patients with one or two comorbidities did not present critical symptoms. Most of the critical cases had at least five comorbidities compared to those with 3 or 4 comorbidities (33.3% versus 8.3%; P = 0.038). The highest incidence of critical COVID-19 (41.7%) was among those with 7 comorbidities. Compared to patients with 4 or fewer comorbidities, patients with 5 (n = 15), 6 (n = 4), and 7 (n = 7) comorbidities were more hospitalized at ICU (above 70%, P = 0.025) and had a higher need for intubation support (above 60%, P = 0.038), and presented higher 30-day mortality (6.7, 25, and 28.6%, respectively; P = 0.002), which can be attributed to the declined clinical outcome of patients with 5 or more comorbidities in moderate-to-critical COVID-19 infection. Conclusions: This study demonstrated a positive association between the severity of COVID-19 and the number of predisposed comorbidities, which leads to poor clinical outcomes.


  • Open Access

    Additional baricitinib loading dose improves clinical outcome in COVID-19

    by Jahidul Hasan, Raihan Rabbani, Ahmad Mursel Anam, Shihan Mahmud Redwanul Huq

    Pneumonia associated with coronavirus disease 2019 (COVID-19) has been accounted for high mortality rate in severe COVID-19 worldwide, and additional serious scarcity of standard and effective anti-inflammatory drug in COVID-19 pneumonia management is a big challenge. Baricitinib, a Janus kinase (JAK) inhibitor, is a promising drug in COVID-19 pneumonia. This study aims to compare the clinical outcome of moderate-to-severe COVID-19 pneumonia treated with baricitinib with or without a loading dose. This prospective case-control study enrolled 37 adult patients where 17 patients (control) received baricitinib at 4 mg oral daily dose and 20 patients (case) received an additional single 8 mg oral loading dose. The median day to gain blood oxygen saturation level ≥95% (in room air) and return in normal breathing function were lower in case group than the control group. The requirement of intensive care unit and mechanical ventilation support was higher in the control group than in the case group [29.4% (N = 17)/10% (N = 20), P < 0.05; 11.8% (N = 17)/5% (N = 20), P > 0.05), respectively]. Thus, an additional loading dose of baricitinib revealed better clinical outcome of patients with COVID-19 pneumonia.


  • Open Access

    Critical Care Pharmacist Using Free Drug-Interaction Checker Mobile Apps Can Ensure Medication Safety in Critically Ill Patients

    by Jahidul Hasan, Raihan Rabbani, Sitesh C Bachar

    Background: Critical care pharmacists (CCPs) have a key role in ensuring medication safety by screening drug-drug interactions (DIs) in polypharmacy prescriptions, mostly in critically ill patients. The drug-interaction checker mobile apps (DICMA) are freely available for smartphones. Objectives: The current study aimed to assess the utilization of smartphone-based free mobile apps by CCPs for ensuring drug-drug interaction-free polypharmacy prescriptions in critically ill patients. Methods: This observational study was conducted in an intensive care unit. Critical care pharmacists (CCPs) checked the medications of polypharmacy prescriptions to detect DIs or potential drug-drug interactions (PDIs) using free DICMA installed on their smartphones. DIs/PDIs were sent to physicians as suggestions, and the prescriptions were modified accordingly. Results: CCPs screened 2,967 prescriptions, where 11,128 and 3,932 DIs and PDIs were identified, respectively. Prescriptions with 6 to 10 medications and prescription with more than 10 medications, on average, had 3.28 and 7.53 DIs, respectively, and 1.42 and 4.7 PDIs, respectively. Physicians accepted 95.85% (n = 3,932) of PDI suggestions from CCPs and modified prescriptions, accordingly. CCPs reported a satisfaction level of 4 (on a scale of 5) concerning the use of free DICMA. Conclusions: Drug-drug interactions-free polypharmacy prescriptions can ensure medication safety in patients. CCPs are professionally responsible for this task, but resource-limited setups do not provide them scopes to accomplish this task efficiently. In this study, CCPs ensured medication safety in the prescriptions of critically ill patients efficiently using free DICMA installed on their smartphones.


  • Open Access

    Comparative Evaluation of Linezolid and Teicoplanin in the Treatment of Ventilator-Associated MRSA Pneumonia: A Single-Center Experience

    by Jahidul Hasan, Shahzadi Sayeeda Tun Nessa, Raihan Rabbani

    Background: Ventilator-associated pneumonia (VAP) caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious infection in an intensive care unit (ICU). Ventilator-associated MRSA pneumonia (VAMP) in critically ill patients causes a high rate of mortality. Objectives: This study mainly aimed to compare the clinical outcomes and associated drug safety perspective of linezolid and teicoplanin in VAMP treatment. Methods: This retrospective study included 98 adult ICU patients with VAMP, where 42 patients (LZD group) and 56 patients (TPN group) received a standard dose of linezolid and teicoplanin, respectively, for their VAMP treatment. Adverse reactions associated with linezolid and teicoplanin were considered. Clinical outcomes and 30-day mortality rates were compared in both groups. Results: The LZD group showed a higher MRSA eradication rate (97%, n = 34) than the TPN group (94.3%, n = 53) (P = 0.034). The linezolid and teicoplanin therapy was suddenly discontinued in 19% and 5.3% of the patients in the LZD and TPN groups, respectively, before completing the full duration of antibiotic therapy due to developed adverse drug reactions (ADRs), including thrombocytopenia (LZD/TPN groups: 7/1 event), tachycardia (LZD group: 1 event), and nephrotoxicity (TPN group: 2 events). This discontinuation increased the total duration of antibiotic therapy in 19% (n = 42) and 5.3% (n = 56) of the patients (P = 0.034) in the LZD and TPN groups, respectively. Conclusions: VAMP is a life-threatening event in critically ill ICU patients worldwide. In this study, teicoplanin showed better clinical outcomes with a certain higher level of drug safety compared to linezolid in the treatment of ventilator-associated MRSA pneumonia.


  • Open Access

    Prolonged QTc: "Mind the Gap"

    by Ahmad Mursel Anam, Raihan Rabbani, Farzana Shumy, M Mufizul Islam Polash, M Motiul Islam, Arm Nooruzzaman, Mirza Nazim Uddin

    We report a case of drug induced torsades de pointes, following acquired long QT syndrome. The patient got admitted for shock with acute abdomen. The initial prolonged QT-interval was missed, and a torsadogenic drug was introduced post-operatively. Patient developed torsades de pointes followed by cardiac arrest. She was managed well and discharged without complications. The clinical manifestations of long QT syndromes, syncope or cardiac arrest, result from torsades de pointes. As syncope or cardiac arrest have more common differential diagnoses, even the symptomatic long QT syndrome are commonly missed or misdiagnosed. In acquired long QT syndrome with no prior suggestive feature, it is not impossible to miss the prolonged QT-interval on the ECG tracing. We share our experience so that the clinicians, especially the junior doctors, will be more alert on checking the QT-interval even in asymptomatic patients. DOI: http://dx.doi.org/10.3329/bccj.v2i1.19970 Bangladesh Crit Care J March 2014; 2 (1): 44-45